Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VIR - Vir Biotechnology Inc


IEX Last Trade
8.25
-0.050   -0.606%

Share volume: 552,855
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$8.30
-0.05
-0.60%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
15%
Profitability 18%
Dept financing 5%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-5.82%
1 Month
-18.54%
3 Months
-20.50%
6 Months
-28.79%
1 Year
-35.97%
2 Year
-66.08%
Key data
Stock price
$8.25
P/E Ratio 
-2.34
DAY RANGE
$8.16 - N/A
EPS 
-$3.58
52 WEEK RANGE
$7.61 - $13.09
52 WEEK CHANGE
-$0.34
MARKET CAP 
1.129 B
YIELD 
N/A
SHARES OUTSTANDING 
136.640 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.63
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$543,213
AVERAGE 30 VOLUME 
$709,208
Company detail
CEO:
Region: US
Website: vir.bio
Employees: 562
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

Recent news